Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study

Trial Profile

Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs TNT 009 (Primary)
  • Indications Autoimmune disorders; Autoimmune haemolytic anaemia; Bullous pemphigoid; Haematological disorders; Renal transplant rejection
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Bioverativ; True North Therapeutics
  • Most Recent Events

    • 28 Jun 2017 According to Bioverativ Media Release, True North Therapeutics has been acquired by Bioverativ.
    • 27 Jun 2017 Trial design of the study presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top